Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Carcinoma, Renal Cell 6Kidney Neoplasms 4Leukemia, Myeloid, Chronic-Phase 3Carcinoma, Hepatocellular 3Unspecified Adult Solid Tumor, Protocol Specific 2Polycythemia Vera 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Leukemia 2Hepatitis B, Chronic 2Fallopian Tube Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Thrombocytosis 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Osteosarcoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplasms 1

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21venetoclax 20Standard of Care 20Sirolimus 20Azacitidine 20Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × peginterferon alfa-2b × Clear all
NCT02634294 2023-03-16

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Completed
30 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡